Desk Notes Cogstate Ltd (ASX: CGS) – Building a Global Leader in Cognitive Assessments Bynathan@prenzlergroup.com.au 14/10/202614/10/2026
Desk Notes | ILA Island Pharmaceuticals (ASX: ILA) – The Path to Approval Without a Human Efficacy Trial Bynathan@prenzlergroup.com.au 08/10/202608/10/2026
Desk Notes | ENP Entropy Neurodynamics Limited (ASX: ENP) – Sector Momentum Builds Ahead of ENP’s Next Clinical Readouts Bynathan@prenzlergroup.com.au 30/09/202601/10/2026
Desk Notes | NTI Neurotech International Ltd (ASX: NTI) – First Patient Dosed, Pivotal Study Begins Bynathan@prenzlergroup.com.au 23/09/2026
ALA | Desk Notes Arovella Therapeutics (ASX: ALA) – Arovella Nears First Patient Dosing with ALA-101 Bynathan@prenzlergroup.com.au 15/09/202623/09/2026
Desk Notes | OIL Optiscan Imaging Limited (ASX: OIL) – Optiscan Builds Toward Dual FDA Submissions Bynathan@prenzlergroup.com.au 08/09/202608/09/2026
ACW | Desk Notes Actinogen Medical Ltd (ASX: ACW) – Xanamem Approaches a Defining Readout Bynathan@prenzlergroup.com.au 02/09/2026
Desk Notes | PAR Paradigm Biopharmaceuticals (ASX: PAR) – Zilosul Approaches Its First Phase 3 Read Out Bynathan@prenzlergroup.com.au 25/08/202625/08/2026
Desk Notes | OSL OncoSil Medical (OSL) – Breaks Into the US Bynathan@prenzlergroup.com.au 18/08/202618/08/2026
Desk Notes | ENP Entropy (ENP) – 72 Patients, Nine Cohorts, Eight Disorders: Entropy Broadens the Platform Bynathan@prenzlergroup.com.au 04/08/202613/08/2026
